Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Vatican Speaker David H. Ahrenholz, MD, FACS
David H. Ahrenholz, MD, FACS
http://celltherapyconference2016.com/2016/03/04/david-h-ahrenholz-md-facs/
Classes 2...16 --- 66mm
Class 18 --- 38mm
As a result, at least $104.9 million of claims senior to those held by members in Classes 19, 21 and 22 must be paid in full prior to those classes being eligible to receive LTIs or distributions on account thereof.
Golden Parachute claims going to go away soon?
NOTICE OF AFFIRMANCE OF FDIC FINAL DETERMINATIONS REGARDING
APPLICATIONS TO MAKE PAYMENTS PURSUANT TO 12 C.F.R. § 359
http://www.kccllc.net/wamu/document/0812229160426000000000001
Contemporaneously herewith, the Trust has provided notice of the
final adjudication of APA Action II (the court previously received notification regarding APA
Action I) to United States District Judge Sleet and is seeking to expeditiously resolve that matter
as well.
I agree.I was wondering about his statements about shareholder value and mis guiding the shareholders and almost lost value of shares.I am down to 10% of my investment, lost value in six figures.Whatever GC and other BODs did ethically is definitely not encouraging.
"OR" means what in WMILT?
On or shortly after the Effective Date, the Liquidating Trust Assets were transferred to the Trust pursuant to the Plan for the benefit of certain holders of claims against, or equity interests in, the Debtors (the “Trust Beneficiaries”). Trust Beneficiaries who were
projected to receive value on account of their Allowed Claims (as defined in the Plan) against the Debtors have been issued LTIs evidencing their right to receive distributions from the Trust if and to the extent sufficient cash is available with respect thereto. If and
when distributions from the Trust become available to Trust Beneficiaries who have not received LTIs to date, additional LTIs will be issued to such Trust Beneficiaries in accordance with the Plan and the distribution priorities that are summarized in Annex C of the Trust Agreement
Do you have one for WMILT?. That should be transparent and openly explain to shareholders what they can expect for common equity,after 8 yrs.
Its a biotech company with on going R&D.Where do they get any revenue from with out having a product?.I dont support what the CEO and BOD had been doing.Company spun out its products such as Lympro and MS Precise, i see value returning to shareholders due to that and it should happen some time in 2Q.Company hired Brian Harvey who actually worked with FDA closely (if i am not wrong)and i hope, his main tasks would be getting RPDD approvals, that also should happen pretty soon in 2Q.For these reasons, i am not selling even a single share.
This might happen after shareholders approval in June.Any thing can happen between today and before June 6th.Example, company might get approval on RPDD and the stock could skyrocket.And imho, after the reverse split, and immediately company can be listed on NASDAQ or NYSE.The company is asking for authorization of 500mm shares, it is not issuing shares, just authorizing.
Won't respond...
NYSE or NASDAQ....eom?
So each share is valued at $1.12 ?
to purchase additional aggregate principal amount of $1,555,556 (including 10% OID) of Notes and Warrants to purchase 1,400,000 shares of common stock upon effectiveness of a registration statement (the "Registration Statement") registering the common stock underlying the Notes and Warrants or earlier as mutually agreed between the investors and the Company and an additional $1,388,889 (including 10% OID) of Notes and Warrants to purchase 1,250,000 shares of common stock on the 61st day after effectiveness of the Registration Statement or earlier as mutually agreed between the investors and the Company.
Who did receive 1.88B initial payment by JPMC?
Who has around 1.88B + 850mm paid by WMI?
Who did receive monies from 363 assets sales?
I am talking about this.
http://www.kccllc.net/wamu/info/3950
Click --- Working
WMI Liquidating Trust v. Federal Deposit Insurance Corporation et al., Case No. 14-50435
Click --- Not working
Willingham et al v. Washington Mutual, Inc., et al. (closed), Case No. 10-51297
Official Committee of Equity Security Holders v. Washington Mutual, Inc., et al. (closed), Case No. 10-50731
Washington Mutual, Inc. et al v. JPMorgan Chase Bank, N.A. et al, Case No. 09-50934
JPMorgan Chase Bank, National Association et al v. Washington Mutual, Inc. et al. (closed), Case No. 09-50551
Dockets missing on KCC
Some are there such as WMILT vs FDIC, but some are completely eliminated and hence.....some thing up soon?
Missing dockets under adversary cases, they were there recently!
Washington Mutual, Inc. et al v. JPMorgan Chase Bank, N.A. et al, Case No. 09-50934
JPMorgan Chase Bank, National Association et al v. Washington Mutual, Inc. et al. (closed), Case No. 09-50551
Check claim # 1738 for about 4B, never closed.
If FDIC was released, how come there is a case
"WMI Liquidating Trust v. Federal Deposit Insurance Corporation et al., Case No. 14-50435"
http://www.kccllc.net/wamu/info/3950
And as per 363 sale, TPS was transferred,sold and lien free from WMI to JPM by FDIC pursuant to GSA.If all the assets were sold based on P&A, why FDIC was again selling something using 363 and GSA?.
And if there is nothing left, why did WMILT mentioned in its recent 10K that there are 5 subsidiaries and some assets were put a value of zero, where the exact value is unknown.It could be 1 dollar or 33B, we never know unless the case gets closer to completion.WMI had 133 subsidiaries at the time of BK.They were consolidated during ch11.
ESS CLINICAL TRIAL GETTING READY
https://clinicaltrials.gov/ct2/show/NCT01655407?term=Engineered+Skin+Substitutes&rank=1
JP Morgan readies mortgage-backed deal
http://www.efinancialnews.com/story/2016-03-15/jp-morgan-readies-mbs?mod=rss-home
JPM acquired 176B mortgage assets from wamu and now selling securities worth 173 B as per form s-3 filed yesterday.
Did JPM pay back the estate for JPM assumed liabilities as per GSA and POR?
"(5) JPMC shall assume the JPMC Assumed Liabilities in
connection with the assets it receives pursuant to the Global Settlement
Agreement and, on or after the Effective Date, JPMC shall pay or fund the
payment of Allowed JPMC Assumed Liability Claims; and"
LINCOLN PARK
The sale or issuance of our common stock to Lincoln Park may cause dilution and the sale of the shares of common stock acquired by Lincoln Park, or the perception that such sales may occur, could cause the price of our common stock to fall
On March 7, 2014, we entered into the Purchase Agreement with Lincoln Park, pursuant to which Lincoln Park has committed to purchase up to $20,000,000 of our common stock. Concurrently with the execution of the Purchase Agreement on March 7, 2014, we issued 4,000,000 shares of our common stock to Lincoln Park for a total purchase price of $400,000 in the Initial Purchase under the Purchase Agreement and 6,000,000 Initial Commitment Shares to Lincoln Park as a fee for its commitment to purchase additional shares of our common stock under the Purchase Agreement. The additional shares that may be sold pursuant to the Purchase Agreement may be sold by us to Lincoln Park at our discretion from time to time over a 30-month period commencing June 17, 2014.
Other than with respect to the Initial Purchase by Lincoln Park under the Purchase Agreement, the purchase price for the shares that we may sell to Lincoln Park under the Purchase Agreement will fluctuate based on the market price of our common stock. Depending on market liquidity at the time, sales of such shares may cause the market price of our common stock to fall.
We generally have the right to control the timing and amount of any sales of our shares to Lincoln Park, except that, pursuant to the terms of our agreements with Lincoln Park, we would be unable to sell shares to Lincoln Park if and when the closing sale price of our common stock is below $0.04 per share, subject to adjustment as set forth in the Purchase Agreement. Additional sales of our common stock, if any, to Lincoln Park will depend upon market conditions and other factors to be determined by us. As such, other than the Initial Purchase, Lincoln Park may ultimately purchase all, some or none of the shares of our common stock that may be sold pursuant to the Purchase Agreement and, after it has acquired shares, Lincoln Park may sell all, some or none of those shares. Therefore, sales to Lincoln Park by us could result in substantial dilution to the interests of other holders of our common stock. Additionally, the sale of a substantial number of shares of our common stock to Lincoln Park, or the anticipation of such sales, could make it more difficult for us to sell equity or equity-related securities in the future at a time and at a price that we might otherwise wish to effect sales.
Disagree.PIPE structure allows the investors
to invest upon a preagreement with a company
to meet certain price target,for ex. 0.04 cents by Marc 31,2016.
The investors starting to short the stock to that certain price ,convert their preferreds and get the cheap shares after reaching the bottom so that making money both ways of the stock movement,mean while long time shareholders get panicked and sell the shares AJMHO.
So they grab the cheap shares at a very very discounted price?.Wow, this is how they become rich like Josh.
RPDD approval due from FDA
AN FRANCISCO, February 5, 2016 /PRNewswire/ --
Amarantus BioScience Holdings, Inc. (OTCQB: AMBS), a biotechnology company focused on developing products for Regenerative Medicine, Neurology and Orphan Diseases, announced that it has requested Rare Pediatric Disease Designation (RPDD) from the US Food and Drug Administration (FDA) for treating retinitis pigmentosa (RP) with MANF. MANF was previously granted orphan drug designation (ODD) by the US FDA in December 2014.
The FDA defines a "rare pediatric disease" as a disease that affects fewer than 200,000 individuals in the U.S. primarily aged from birth to 18 years. Under the FDA's Rare Pediatric Disease Priority Review Voucher program, a sponsor who receives an approval of a new drug application (NDA) or biologics license application (BLA) for a rare pediatric disease may be eligible for a voucher, which can be redeemed to obtain expedited FDA review for any subsequent marketing application. Vouchers may be sold or transferred by the recipient; in the last 6 months, 2 priority review vouchers have been sold for a combined $595M in cash.
In December 2015, Amarantus submitted ODD and RPDD applications to the US FDA for engineered skin substitute in the treatment of Giant Congenital Hairy Nevus (GCMN), in addition to its ODD application to the US FDA for eltoprazine in the treatment of Parkinson's disease levodopa-induced dyskinesia (PD-LID) submitted in October 2015. The Company expects to receive responses regarding these designation applications in the first quarter of 2016.
You seem to have so much knowledge about the investors and other strategies of the investors.What are you trying to suggest here?.You calling shareholders bagholders and what are you suggesting?.You want shareholders to sell and what?.Are you buying shares or selling?.If you already sold your shares, why do you spend time here day and night?.
Are you trying to panic shareholders?. If you have concerns about the management, you should contact AMBS management and request whatever info is needed for you.Why are you guys working so hard day and night, weekdays and weekends predicting the share price and panicking shareholders like me?.
JMHO
Escrows markers are meant only for distribution of WMIH shares as per the press release made by WMLT last year.
Scenario 1: If FDIC transfers the assets to WMILT and LT inturn transfer those assets to WMIH, Escrow holders such as me, might see value returned thru WMIH shares.
Scenario 2: FDIC directly liquidates the assets of the receivership and directly send it to former shareholders as in any other case of the receivership.I do remember sending a tax form along with ballots during the POR7 approval.
AJHMO.
12 U.S. Code § 1821 (d)11
(d) Powers and duties of Corporation as conservator or receiver
(11) Depositor preference
(A) In generalSubject to section 1815(e)(2)(C) of this title, amounts realized from the liquidation or other resolution of any insured depository institution by any receiver appointed for such institution shall be distributed to pay claims (other than secured claims to the extent of any such security) in the following order of priority:
(i)
Administrative expenses of the receiver.
(ii)
Any deposit liability of the institution.
(iii)
Any other general or senior liability of the institution (which is not a liability described in clause (iv) or (v)).
(iv)
Any obligation subordinated to depositors or general creditors (which is not an obligation described in clause (v)).
(v)
Any obligation to shareholders or members arising as a result of their status as shareholders or members (including any depository institution holding company or any shareholder or creditor of such company).
(B) Effect on State law
(i) In general
The provisions of subparagraph (A) shall not supersede the law of any State except to the extent such law is inconsistent with the provisions of such subparagraph, and then only to the extent of the inconsistency.
(ii) Procedure for determination of inconsistency
Upon the Corporation’s own motion or upon the request of any person with a claim described in subparagraph (A) or any State which is submitted to the Corporation in accordance with procedures which the Corporation shall prescribe, the Corporation shall determine whether any provision of the law of any State is inconsistent with any provision of subparagraph (A) and the extent of any such inconsistency.
(iii) Judicial review
The final determination of the Corporation under clause (ii) shall be subject to judicial review under chapter 7 of title 5.
(C) Accounting report
Any distribution by the Corporation in connection with any claim described in subparagraph (A)(v) shall be accompanied by the accounting report required under paragraph (15)(B).
1815(e)2©
(2) Amount of compensation; procedures
(C) PriorityThe liability of any insured depository institution under this subsection shall have priority with respect to other obligations and liabilities as follows:
(i) SuperiorityThe liability shall be superior to the following obligations and liabilities of the depository institution:
(I)
Any obligation to shareholders arising as a result of their status as shareholders (including any depository institution holding company or any shareholder or creditor of such company).
(II)
Any obligation or liability owed to any affiliate of the depository institution (including any other insured depository institution), other than any secured obligation which was secured as of May 1, 1989.
(ii) SubordinationThe liability shall be subordinate in right and payment to the following obligations and liabilities of the depository institution:
(I)
Any deposit liability (which is not a liability described in clause (i)(II)).
(II)
Any secured obligation, other than any obligation owed to any affiliate of the depository institution (including any other insured depository institution) which was secured after May 1, 1989.
(III)
Any other general or senior liability (which is not a liability described in clause (i)).
(IV)
Any obligation subordinated to depositors or other general creditors (which is not an obligation described in clause (i)).
FDIC stated that "Equity claims are paid in accordance with 12 U.S.C .sec.1821(d)11"
Search the quoted part in google and click the 3rd link for the pdf and look at page 33, the FDIC response for WMI claim.
MMs are in full control
http://www.otcmarkets.com/stock/AMBS/quote
They bring the stock down, accumulate and raise the stock to get profits.
THI @ $40.64
"The Note matures on February 28, 2017 and bears interest at 8% per annum payable at maturity in cash. The Note is convertible at any time at the option of the Company into shares of common stock of THI at a conversion price of $40.64 per share. The Note shall automatically convert into shares of common stock of THI upon a change of control of THI. It is expected that the Note will be assumed by Avant upon consummation of the transaction with THI"
What exactly is going on?.So AVDX will be 40.46 after acquiring THI?
ANICO CASE DISMISSED
https://ecf.dcd.uscourts.gov/cgi-bin/Opinions.pl?2016
Page 31/37
WMB 307B,WMI 133 SUBS,33B ASSETS WITH 8B LIABILITIES
http://gao.gov/products/GAO-15-299
Read the tab with 'View Report' in pdf
who are you warning to and why?.So the company increases authorized shares to(filed with SEC) 500 million and do a reverse split?.What a great theory!.
So true.The interviewer asked the current asset value with out doing any thing,GC mentioned the value of ESS comparing with a similar competitor in the market and valued around $100 million.And also mentioned, AMBS has so many other products.
He is a director of internation infusion
http://www.internationalinfusion.com/new-page-1/
Ofcourse the price is controlled by MMs see the bid and ask, and where the share price is.When they all load up, they might raise.See below the quote for MMs.
http://www.otcmarkets.com/stock/AMBS/quote
SHAKING TO GET VOTING SHARES TO CONTROL?
This shaking the week hands is to acquire more and more shares so that they get the voting in their favor in upcoming proxy?
GREAT LETTER
Meanwhile, i found this on international infusion website.GC and Rubinfeld are connected with them.
http://www.internationalinfusion.com/new-page-1/
And international infusion is invested/investing in AMBS.
So your point is?.
ZACKS PRICE TARGET $5 ON 11/25
Current Recommendation Buy
Prior Recommendation Sell
Date of Last Change 07/12/2015
Current Price (11/24/15) $0.35
Target Price $5.00
UPDATE:
Despite what we believe is aggressive discounting and
downward adjusting of our models based on overly
pessimistic probability assumptions, we are still arriving at a
target price of $5.00 per share. The current market
capitalization is only $4 million. Our target is far more
consistent with that we see as a peer-valuation for similarstage
NASDAQ listed companies. We believe several pending
catalysts over the next 15 months, including the AMDX sales /
spin-off, starting human clinical trials with MANF, reporting
results from the eltoprazine Phase IIb data, and the ESS
Phase IIa data should allow for the realization of a significantly
higher stock price.
http://www.otcmarkets.com/stock/AMBS/research
500Million SHARES ISSUING Vs AUTHORIZING
The company is asking the shareholders to vote to authorize AMBS for increasing issuable shares to 500million from 150million.Why is it doing?
Purpose:
At present, other than in connection with the possible conversion or exercise of securities convertible or exercisable into common stock, as set forth above (each at the option of their respective holders), the Board of Directors has no other plans to issue the additional shares of common stock to be authorized by the Common Shares Increase Amendment. However, it is possible that some of these additional shares could be used in the future for various other purposes without further shareholder approval, except as such approval may be required in particular cases by our charter documents, applicable law or the rules of any stock exchange or other market on which our securities may then be listed. These purposes may include: raising capital, providing equity incentives to employees, officers or directors, establishing strategic relationships with other companies, and expanding the Company’s business or product lines through the acquisition of other businesses or products.
We could also use the additional shares of common stock that will become available pursuant to the Common Shares Increase Amendment to oppose a hostile takeover attempt or to delay or prevent changes in control or management of the Company. Although the proposal to increase the authorized common stock has not been prompted by the threat of any hostile takeover attempt (nor is the Board currently aware of any such attempts directed at the Company), nevertheless, shareholders should be aware that the Common Shares Increase Amendment could facilitate future efforts by us to deter or prevent changes in control of the Company, including transactions in which shareholders of the Company might otherwise receive a premium for their shares over then current market prices. However, the Board of Directors has a fiduciary duty to act in the best interests of the Company's shareholders at all times.